Date: 2016-09-21
Type of information: R&D agreement
Compound: Nanofitins® platform
Company: Affilogic (France) Takeda Pharmaceutical (Japan)
Therapeutic area: CNS diseases
Type agreement: R&D collaboration
Action mechanism: antibody mimetic. Nanofitins® are potent antibody-mimetics, exhibiting high affinity and specificity for capture, targeting and interaction with biomolecules. They can be easily conjugated to other moieties, such as antibodies, small molecules, and nanoparticles, to empower third parties’ molecules, their very small size triggering low impact on the natural properties of such payload. Deriving from a naturally hyperstable scaffold, Nanofitins® are resistant to temperature and pH, stable to proteases, spontaneously refolding. They are produced by simple, scalable, GMPcompliant
bacterial fermentation at very attractive costs or by chemical synthesis.
Affilogic has designed Nanofitins® against 50+ targets to date, including a wide range of circulating antigens (peptides, proteins), membrane receptors for inhibition / modulation / translocation, and complex entities (Virus-like Particles, bacteria, whole cells).
Disease: CNS diseases
Details: * On September 21, 2016, Takeda Pharmaceutical Company and Affilogic jointly announced that the companies have entered into a research collaboration to explore using Affilogic’s proprietary Nanofitins® platform in therapies targeting the central nervous system. Specifically, Affilogic and Takeda, through its research center in San Diego, California, will leverage their respective competencies to validate and optimize Nanofitins® that enable Takeda to deliver biotherapeutic candidates into the brain to address neurological disorders.
Under the terms of the agreement, Affilogic will receive an upfront payment and research funding, and is eligible to receive additional development and sales milestone payments and royalties by Takeda. Takeda will be entitled to commercialize worldwide products incorporating Affilogic Nanofitins® resulting from the collaboration. Further details of the agreement were not disclosed.
Financial terms:
Latest news:
